Dear Editor,

On the occasion of the 2012 annual meeting of the American Society of Human Genetics in San Francisco, the scientific press concluded to a sobering \"genetic influences on disease remain hidden\" after discussing, among others, the progress made in the field of cardiovascular genetics \[[@b1-ad-7-3-216]\]. In a recent attempt to resolve some of the inconsistent findings, Zhang and coworkers \[[@b2-ad-7-3-216]\] have presented a quantitative analysis of *APOC3* variants in coronary heart disease. Unfortunately, only a fraction of the previously published data have been considered and, using the authors' inclusion criteria, over 10000 alleles are missing from the investigation \[[@b3-ad-7-3-216]-[@b8-ad-7-3-216]\]. What is more, incorrect allele counts have led to biased effects for the *Sst*I polymorphism, causing the risk-enhancing allele to become protective \[[@b9-ad-7-3-216]\] and *vice versa* \[[@b10-ad-7-3-216]\]. Allele counts for the T-455C variant also differ from the published data \[[@b11-ad-7-3-216]\] and are further compromised by duplicates from overlapping samples \[[@b11-ad-7-3-216],[@b12-ad-7-3-216]\]. With regard to both T-455C and C-482T, the vast majority of allele frequencies reported in Table 1 of the article \[[@b2-ad-7-3-216]\] are either in error \[[@b11-ad-7-3-216],[@b13-ad-7-3-216]-[@b18-ad-7-3-216]\], missing \[[@b12-ad-7-3-216]\], or entirely fictional \[[@b19-ad-7-3-216]\]. Finally, failure to identify C3175G as a synonym of the *Sst*I polymorphism has led to the omission of more alleles from a publication which served to extract data on T-455C and C-482T \[[@b13-ad-7-3-216]\].

On the whole, the article calls for numerous issues to be ironed out prior to claiming, or to refuting, significant effects of the three *APOC3* variants on coronary heart disease susceptibility.
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In light of Dr. Sands' letter, we have reanalyzed data from our meta-analysis of the association between apolipoprotein C-III gene polymorphisms and coronary heart disease (CHD)\[[@b20-ad-7-3-216]\]. Our original database searches did not recover several references cited by Dr. Sand\[[@b21-ad-7-3-216]-[@b24-ad-7-3-216]\], which we have now included, and we were unable to extract data useful for our analysis from two other references \[[@b25-ad-7-3-216]-[@b26-ad-7-3-216]\]. We have reexamined additional studies referred to by Dr. Sand \[[@b27-ad-7-3-216]-[@b33-ad-7-3-216]\] and recalculated our results accordingly.

The new calculations still show an association between the APOC3 SstI polymorphism and CHD under allelic contrast (*P* \<0.0001, OR = 1.17, 95% CI = 1.08-1.27), dominant genetic (*P* = 0.001, OR = 1.17, 95% CI = 1.07-1.29), and recessive genetic (*P* = 0.01, OR = 1.36, 95% CI = 1.07-1.73) models; between the APOC3 T-455C polymorphism and CHD under allelic contrast (C vs. T, *P* = 0.007, OR = 1.19, 95% CI = 1.05-1.35) and dominant genetic (CT+CC vs. TT, *P* = 0.0004, OR = 1.26, 95% CI = 1.11-1.43), but no longer recessive genetic (CC vs. CT+TT, *P* = 0.12, OR = 1.25, 95% CI = 0.95-1.66) models; and no association between the APOC3 C-482T polymorphism and CHD under allelic contrast (T vs. C, *P* = 0.59, OR =1.02, 95%CI = 0.95-1.10), dominant genetic (TT+TC vs. CC, *P* = 0.17, OR = 1.08, 95% CI = 0.97-1.20)or recessive genetic (TT vs. TC+CC, *P* = 0.41, OR = 0.94, 95% CI = 0.82-1.09) models. Our meta-analysis suggests that the APOC3 SstI polymorphism significantly increases, the APOC3 T-455C polymorphism may increase, and the APOC3 C-482Tpolymorphism shows no association with CHD susceptibility.

We sincerely apologize for the errors in our article.
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